Sanofi's dengue fever vaccine proves effective against three strains; Elan CEO defends against 'bapi' fears;

NEW! Conversations on  Twitter :

 @FierceBiotech: Sanofi sets out to reinvent itself in Genzyme's biotech image. More | Follow @FierceBiotech

 @JohnCFierce: Busy biotech investor NEA unveils $2.6B global fund--says venture money controlled by a smaller number of global players. Story | Follow @JohnCFierce

 @RyanMFierce: China market may grow faster than U.S. for trials tech eClinical, but I don't see that hurting U.S. software cos. Article | Follow @RyanMFierce

> Sanofi ($SNY) reported that its dengue vaccine effectively guarded against three of four strains of dengue fever. Dengue fever threatens three billion people around the globe. Story

> Fighting back against fears that bapineuzumab is on track to self-destruct after the first of four Phase III studies ended in failure, Elan CEO Kelly Martin said that the company was built to "move forward with or without" the Alzheimer's therapy. Elan sold the drug to J&J ($JNJ) and Pfizer ($PFE), retaining a large royalty on sales. Martin had planned to retire by this point, but agreed to stay on until bapi's fate was known. Story

> Idenix Pharmaceuticals ($IDIX) says the FDA has granted fast track designation for IDX719 for the treatment of chronic hepatitis C infection. Release

> CytRx launched a Phase Ib clinical trial to "determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies." Aldoxorubicin is a tumor-targeting conjugate of doxorubicin. Release

Pharma News

 @FiercePharma: U.K.'s rolling out flu vax program for all kids, using AstraZeneca's spray immunization. Report | Follow @FiercePharma

> Glaxo sales slump in Europe, US on price cuts, generics. News

> Lilly sales reel from Zyprexa loss, but Cymbalta offers aid. Article

> Generics take a billion-dollar bite from Bristol-Myers sales. More

> FDA spanks Sanofi vaccine plant for violations. Item

Medical Device News

@FierceMedDev: Now that SCOTUS has upheld the national health reform law, winners and losers are lining up. Slideshow | Follow @FierceMedDev

 @MarkHFierce: NEA closes its massive VC fund--the 14th--with $2.6 billion in committed capital. Release | Follow @MarkHFierce

 @DamianFierce: Thermo Fisher posts 9% Q2 revenue growth on strong diagnostics sales. Story | Follow @DamianFierce

> Angioplasty with nitinol stents shows promise as PAD treatment. Item

> Edwards scores Q2 growth on heart valve sales. News

Drug Delivery News

> Chiasma closes multimillion funding to support oral acromegaly trial. Story

> Gels and rings--using drug delivery to protect against HIV. Article

> Taking insulin could be as simple as moisturizing. News

> Microneedles deliver drugs where eyedrops can't. More

Biomarkers News

> Genetic markers pinpoint medulloblastoma as four diseases, not one. News

> Blood test could predict risk of death from hypertension. Story

> Could markers manage milk allergy? More

> Sodium in the brain marks disability in MS. Article

And Finally… A new study finds that kids are rarely included in clinical studies, even when they make up a big share of the patient population. Story

 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.